进展期非小细胞肺癌化疗获益相关标志物研究  

A Study on Markers Related to Chemotherapy Benefit of Advanced Non-Small Cell Lung Cancer

作　　者：陈晓伟[1] 靳义[1] 贺平 杨海龙 王丁丁 CHEN Xiaowei;JIN Yi;HE Ping;YANG Hailong;WANG Dingding(Department of Thoracic Surgery, Harrison International Peace Hospital, Hengshui 053000, China)

机构地区：[1]哈励逊国际和平医院胸外科,河北衡水053000

出　　处：《标记免疫分析与临床》2022年第1期134-139,共6页Labeled Immunoassays and Clinical Medicine

基　　金：2020年衡水市科技计划项目(编号:2020014054Z)。

摘　　要：目的研究进展期非小细胞肺癌(NSCLC)化疗获益相关标志物的临床应用价值。方法选取2017年1月至2018年3月衡水市人民医院接受化疗的200例进展期NSCLC患者作为研究对象,均行顺铂或洛铂+吉西他滨、顺铂或洛铂+培美曲塞化疗方案化疗,化疗2个周期后根据疗效分为有效组(n=132)和无效组(n=68),比较两组临床资料、化疗前、化疗1个周期后、2个周期后血清微小RNA(miRNA)-137-3p、miR-1255b-5p、miR-379-5p水平,采用受试者工作特征(ROC)曲线评价化疗2个周期后各指标评估疗效的价值,所有患者均随访3年,统计预后情况(死亡、存活),比较不同预后患者化疗2个周期后血清miR-137-3p、miR-1255b-5p、miR-379-5p水平,分析各指标与进展期NSCLC预后的关联性。结果无效组TNM分期Ⅳ期患者占比(41.18%)、分化程度为中、低分化患者占比(85.29%)、有淋巴结转移患者占比(36.76%)均高于有效组(P<0.05);无效组化疗前、化疗1个周期后、2个周期后血清miR-137-3p、miR-1255b-5p、miR-379-5p水平均低于有效组(P<0.05);化疗2个周期后血清miR-137-3p、miR-1255b-5p、miR-379-5p水平评估化疗效果为无效的曲线下面积(AUC)均>0.8,各指标联合评估的AUC最大,为0.938;进展期NSCLC患者3年生存率为28.50%,死亡患者化疗2个周期后血清miR-137-3p、miR-1255b-5p、miR-379-5p水平均低于存活患者(P<0.05);化疗2个周期后血清miR-137-3p、miR-1255b-5p、miR-379-5p与NSCLC患者预后显著相关(P<0.05)。结论血清miR-137-3p、miR-1255b-5p、miR-379-5p水平是与进展期NSCLC患者化疗获益相关的标志物,在评估化疗疗效方面具有较高应用价值,且与患者预后显著相关。Objective To study the clinical application value of markers related to chemotherapy benefit of advanced non-small cell lung cancer(NSCLC).Methods 200 patients with advanced NSCLC who received chemotherapy in Hengshui People’s Hospital from January,2017 to March,2018 were selected as the research objects.All patients received treatments of cisplatin or lobaplatin+gemcitabine,cisplatin or lobaplatin+pemetrexed chemotherapy.After two cycles of chemotherapy,these patients were divided into the effective group(n=132)and ineffective group(n=68)according to the curative effect.After two cycles of chemotherapy,the levels of serum microRNA(miRNA)-137-3p,miR-1255b-5p and miR-379-5p were measured.Receiver operating characteristic(ROC)curve was drawn to evaluate the efficacy of each index after two cycles of chemotherapy.All patients were followed up for 3 years,and the prognosis(death and survival)was analyzed.The correlation between each index and the prognosis of advanced NSCLC was analyzed.Results The proportion of patients with TNM stageⅣ(41.18%),moderately and poorly differentiated(85.29%)and lymph node metastasis(36.76%)in the ineffective group were higher than those in the effective group(P<0.05);Serum levels of miR-137-3p,miR-1255b-5p and miR-379-5p in the ineffective group were lower than those in the effective group before chemotherapy,one cycle after chemotherapy and two cycles after chemotherapy(P<0.05);After two cycles of chemotherapy,the area under the curve(AUC)of serum miR-137-3p,miR-1255b-5p and miR-379-5p levels that were ineffective in evaluating the effect of chemotherapy were all>0.8,and the AUC of the combined evaluation of all index was the largest,which was 0.938;The 3-year survival rate of patients with advanced NSCLC was 28.50%.Serum levels of miR-137-3p,miR-1255b-5p and miR-379-5p in expired patients after 2 cycles of chemotherapy were lower than those in the survival patients(P<0.05);After two cycles of chemotherapy,serum miR-137-3p,miR-1255b-5p and miR-379-5p were significantly correlated w

关 键 词：非小细胞肺癌 进展期 化疗 微小RNA 疗效 预后 

分 类 号：R734.2[医药卫生—肿瘤]